相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
David M. Goldenberg et al.
BLOOD (2009)
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles et al.
BLOOD (2008)
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
David V. Gold et al.
CANCER RESEARCH (2008)
Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics
Edmund A. Rossi et al.
CANCER RESEARCH (2008)
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
Eva Kimby et al.
LEUKEMIA & LYMPHOMA (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model
Robert M. Sharkey et al.
RADIOLOGY (2008)
Multifunctional antibodies by the dock-and-lock method for improved cancer Imaging and therapy by pretargeting
David M. Goldenberg et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Targeting IFN-α to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities
Tzu-Hsuan Huang et al.
JOURNAL OF IMMUNOLOGY (2007)
The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity
Chien-Hsing Chang et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
Josette Carnahan et al.
MOLECULAR IMMUNOLOGY (2007)
Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab
Rhona Stein et al.
BLOOD (2006)
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
EA Rossi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes
JA Carrero et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods
RM Sharkey et al.
CLINICAL CANCER RESEARCH (2005)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
A Takaoka et al.
NATURE (2003)
Effect of pegylation on pharmaceuticals
JM Harris et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys
BL Osborn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Interferon-alpha in tumor immunity and immunotherapy
F Belardelli et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function
P Matarrese et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
SM Santini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha
M Mecchia et al.
GENE THERAPY (2000)
分享论文
